Norbert Moldován
Has grant
Senior bioinformatician
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Augmenting Datasets using Diffusion Models: Leveraging Machine Learning for Liquid Biopsy and cfDNA Analysis
Open Date: 2024-01-01
Close Date: 2024-07-01
Grant: Close
Exploring full-length circular RNA from liquid biopsies for cervical cancer detection
Open Date: 2023-08-01
Close Date: 2024-07-01
Grant: Close
Talent award
Open Date: 2019-01-01
Close Date:
Grant: Close
Using OMICS approach for the analysis of viral gene expression
Open Date: 2018-09-01
Close Date: 2023-02-28
Grant: Close
Multiplatform analysis of herpesvirus gene expression
Open Date: 2018-09-01
Close Date: 2023-08-31
Articles (3)
Year:
2026
Background While cell-free DNA (cfDNA) is a promising biomarker for cancer diagnosis and monitoring, there is limited agreement on optimal cfDNA collection and extraction protocols as well as analysis pipelines of the corresponding cfDNA sequencing data. In this article, we address the latter by studying the effect of various bioinformatics preprocessing choices on derived genetic and epigenetic cfDNA features and study how observed feature differences influence the downstream task of separating between healthy and cancer cfDNA samples. Results Using low-pass whole-genome cfDNA sequencing data from 20 lung cancer and 20 healthy samples, we assessed the influence of various preprocessing settings, such as read trimming, filtering of secondary alignments, and choice of genome build, as well as practices such as downsampling or selecting for a short fragment on derived cfDNA features, including cfDNA fragment size, fragment end motifs, copy number alterations, and nucleosome footprints. Our results demonstrate that the analyzed features are robust to common preprocessing choices but exhibit variable sensitivity to sequencing coverage. Fragment length statistics and end motifs are the least affected by low coverages, whereas nucleosome footprint analysis is very sensitive to them. Our findings confirm that selecting for shorter fragments enhances cancer-specific signals but, by removing data, also reduces signals in general. Interestingly, we find that fragment end motif analysis benefits the most from in silico size selection. We also observe that the filtering of low-quality and secondary alignments and choice of genome build result in slight improvements in cancer classification performance based on nucleosome coverage and copy number features. Conclusions Altogether, we conclude that cfDNA analysis is minimally affected by different bioinformatics preprocessing settings, but we describe some synergistic effects between analytical approaches, which can be leveraged to improve cancer detection.
Year:
2025
Shallow genome-wide cell-free DNA (cfDNA) sequencing holds great promise for non-invasive cancer monitoring by providing reliable copy number alteration (CNA) and fragmentomic profiles. Single nucleotide variations (SNVs) are, however, much harder to identify with low sequencing depth due to sequencing errors. Here we present Nanopore Rolling Circle Amplification (RCA)-enhanced Consensus Sequencing (NanoRCS), which leverages RCA and consensus calling based on genome-wide long-read nanopore sequencing to enable simultaneous multimodal tumor fraction estimation through SNVs, CNAs, and fragmentomics. Efficacy of NanoRCS is tested on 18 cancer patient samples and 3 healthy controls, demonstrating its ability to reliably detect tumor fractions as low as 0.24%. In vitro experiments confirm that SNV measurements are essential for detecting tumor fractions below 2%. NanoRCS provides the opportunity for cost-effective and rapid processing, which aligns well with clinical needs, particularly in settings where quick and accurate cancer monitoring is essential for personalized treatment strategies.
Year:
2024
Collaborators (6)
Jeroen de Ridder
University Medical Center Groningen
Jan Lipfert
Full professor (Chair of Experimental Physics I)
Utrecht University
Ronald P. Zweemer
University Medical Center Groningen
Zsolt Balázs
Senior Researcher
University Hospital of Zurich
Idris Bahce
Amsterdam University Medical Centers
Florent Mouliere
Team leader
Cancer Research UK Manchester Institute
Make your next move.
Prepare your application
Review drafts before you send them.